| 3,708 | 66 | 23 |
| 下载次数 | 被引频次 | 阅读次数 |
高尿酸血症(HUA)是由于人体嘌呤代谢异常或尿酸排泄减少所导致的一类尿酸盐浓度过高的疾病.长期以来,HUA被认为与痛风、慢性肾病、糖尿病等疾病有关.回顾了近几年与HUA相关的国内外研究文献,从人体尿酸水平的角度入手,对HUA的机制、相关疾病、治疗等方面的研究进展进行了综述,目的是总结现今的研究成果、热点及新方向,为HUA的后续研究提供一定的思路.
Abstract：Hyperuricemia(HUA) is a disease of excessively high urate concentration caused by abnormal purine metabolism or decreased excretion of uric acid in the human body. For a long time, HUA has been thought to be related to some diseases such as gout, chronic kidney disease, and diabetes. This article reviews the literatures on HUA in recent years, starting from the point of view of human uric acid level, the progress of research mechanisms and the treatment of HUA were reviewed. The purpose is to summarize current research results, hotspots and new directions, and provide certain ideas for the follow-up research of HUA.
[1] WOODWARD OM.ABCG2:the molecular mechanisms of urate secretion and gout[J].American journal of physiology Renal physiology,2015,309(6):485-488.
[2] MAJOR TJ,DALBETHN,STAHL EA ,et al.An update on the genetics of hyperuricaemia and gout[J].Nat Rev Rheumatol,2018,14(6):341-353.
[3] 孙琳，王桂侠，郭蔚莹.高尿酸血症研究进展[J].中国老年学杂志，2017,37(4):1034-1038.
[4] 裴芳，裴华，夏中华，等.高尿酸血症和痛风的表观遗传学研究进展 [J].生理科学进展，2019,50(3):175-180.
[5] GRAYSON P C,KIM S Y,LAVALLEY M,et al.Hyperuricemia and incident hypertension:A systematic review and meta-analysis [J].Arthritis Care Res,2011,63(1):102-110.
[6] MASANARI K,KOICHIRO N,ICHIRO H,et al.Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases:Five-Year Japanese Cohort Study [J].Hypertension,2017,69(6):1036-1044.
[7] 万晓芸，张芳.中医药治疗高尿酸血症的应用研究进展[J].糖尿病天地，2020,17(4):297-304.
[8] 吕雪霞，胡吉东.高尿酸血症患病率调查及临床影响分析[J].临床检验杂志(电子版),2020,9(1):34-35.
[9] FRéDéRIC L.Gout furonculosis[J].Joint bone spine,2019,86(1):103-111.
[10] SONG M,LI N,YAO Y,et al.Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis[J].J Cell Mol Med,2019,23(8):4970-4979.
[11] MANDAL A K,MOUNT D B.The Molecular Physiology of Uric Acid Homeostasis[J].Annu Rev Physiol,2015,77:323-345.
[12] 丁雪东，彭成璐，李曼曼，等.尿酸转运蛋白与血清尿酸平衡[J].国际药学研究杂志，2018,45(9):665-669.
[13] PARK R J,KANG M G.Association Between Serum Uric Acid and Prediabetes in the Korean General Population[J].Asia Pacific Journal of Public Health,2019,31(8):719-727.
[14] OLOFSSON C,ANDERSTAM B,BRAGFORS-HELIN A C,et al.Effects of acute fructose loading on levels of serum uric acid-a pilot study[J].Eur J Clin Invest,2019,49(1):130-140.
[15] AKIYOSHI N,HIROFUMI N,KEN Y,et al.GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes[J].Ann Rheum Dis,2017,76(5):869-877.
[16] MICHAELC X,CHIO Y,SHARAN K R,et al.Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends:The National Health and Nutrition Examination Survey,2007-2016[J].Arthritis & Rheumatology,2019,71(6):991-999.
[17] GIANLUCA T,PAOLO M,LORENZO C,et al.Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009:a nationwide population-based study[J].Ann Rheum Dis,2013,72(5):694-700.
[18] CHOU C,LAI J S.The epidemiology of hyperuricaemia and gout in Taiwan aborigines[J].Br J Rheumatol,1998,37(3):258-262.
[19] 魏晓珠，苏维，陈望，等.沿海地区人群高尿酸血症患病率及其与SLC2A9基因rs2241480位点多态性的关系[J].临床输血与检验，2020,22(2):160-164.
[20] KUWABARA M,KUWABARA R,HISATOME I,et al.“Metabolically Healthy” Obesity and Hyperuricemia Increase Risk for Hypertension and Diabetes:5-year Japanese Cohort Study[J].Obesity,2017,25(11):1997-2008.
[21] 叶文静，程亚伟，邱晓堂.中医药治疗高尿酸血症的研究进展[J].海南医学，2020,31(9):1187-1190.
[22] 梁国强，尤君怡，马奇翰.吴门三黄汤对高尿酸血症大鼠模型防治作用研究[J].辽宁中医药大学学报，2019,21(8):26-30.
[23] JOHNSON J R,BAKRIS G L,BORGHI C,et al.Hyperuricemia,Acute and Chronic Kidney Disease,Hypertension,and Cardiovascular Disease:Report of a Scientific Workshop Organized by the National Kidney Foundation[J].American Journal of kidney diseases:the official journal of the National Kidney Foundation,2018,71(6):851-865.
[24] STAMP L K,DALBETH N.Prevention and treatment of gout [J].Nature Reviews Rheumatology,2019,15(2):68-70.
[25] WOO K M,JUN C H,KWON-WOOK J,et al.Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients [J].Nephrology (Carlton,Vic),2019,24(7):718-724.
[26] XIAO J,ZHANG X-L,FU C,et al.Soluble uric acid increases NALP3 inflammasome and interleukin-1β expressionin human primary renal proximal tubule epithelial cells through the Toll-likereceptor 4-mediated pathway [J].Int J Mol Med,2015,35(5):1347-1354.
[27] JING X,CHENSHENG F,XIAOLI Z,et al.Soluble monosodium urate,but not its crystal,induces toll like receptor 4-dependent immune activation in renal mesangial cells[J].Mol Immunol,2015,66(2):310-318.
[28] DISHA Z,YAO Y,NINA Z,et al.Analysis of risk factors and their interactions in type 2 diabetes mellitus:A cross-sectional survey in Guilin,China [J].Journal of diabetes investigation,2017,8(2):310 - 318.
[29] XIA Q,ZHANG S-H,YANG S-M,et al.Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus[J].J Chin Med Assoc,2020,83(4):350-356.
[30] LIUF C,HUIJS,SHOUL W,et al.Association of serum uric acid and risk of hypertension in adults:a prospective study of Kailuan Corporation cohort[J].Clin Rheumatol,2017,36(5):1103-1110.
[31] LEE S W,KIM H C,NAM C,et al.Age-differential association between serum uric acid and incident hypertension [J].Hypertens Res,2019,42(3):428-437.
[32] ACCIOLY R E P A,MANDY V,JURAJ S,et al.Serum Uric Acid Levels as an Indicator for Metabolically Unhealthy Obesity in Children and Adolescents[J].Hormone research in paediatrics,2018,19-27.
[33] MARUHASHI T,HISATOME I,KIHARA Y,et al.Hyperuricemia and endothelial function:From molecular background to clinical perspectives[J].Atherosclerosis,2018,278:226-231.
[34] NDREPEPA G.Uric acid and cardiovascular disease[J].Clin Chim Acta,2018,484:150-163.
[35] 周子正，徐琳，高建东.高尿酸血症动物模型研究进展[J].医学综述，2020,26(8):1462-1466.
[36] 冯学轩，刘月姝，饶子亮，等.急、慢性高尿酸血症模型的建立[J].中国比较医学杂志，2020,30(1):74-80.
[37] DALBETH N,CHOI H K,JOOSTEN L A B,et al.Gout [J].Nat Rev Dis Primers,2019,5(1):69-77.
[38] LISA K S,PETER T C,MURRAY B,et al.Allopurinol dose escalation to achieve serum urate below 6 mg/dL:an open-label extension study[J].Ann Rheum Dis,2017,76(12):2065-2070.
[39] WALLACE M C,ROBERTS R L,NANAVATI P,et al.Association between ABCG2 rs2231142 and poor response to allopurinol:replication and meta-analysis[J].Rheumatology (Oxford,England),2018,57(4):656 -660.
[40] KO T M,TSAIC Y,CHEN S Y,et al.Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan:national prospective cohort study[J].BMJ,2015,351(8027):13-14.
[41] White W B,SaagK G,BeckerM A,et al.Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout[J].The New England journal of medicine,2018,378(13):1200-1210.
[42] MIZUKOSHI T,KATO S,ANDO M,et al.Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study):A prospective,randomized,multicentre clinical trial[J].Nephrology,2018,23(11):1023-1030.
[43] 骆贤亮，刘滔，钱忠英，等.降尿酸肽对高尿酸血症的作用及研究进展[J].食品科学，2020,16(8):1-15.
[44] LARYSA S,FEDERICA F,FG C A.Safety and tolerability of available urate-lowering drugs:a critical review[J].Expert Opin Drug Saf,2019,18(4):261-271.
[45] ZANCONG S,A.L C,KATHLEEN W,et al.Lesinurad:Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers [J].Clinical Pharmacology in Drug Development,2019,8(5):657-663.
[46] DAVID FP,KENT R,KIYOSHI N,et al.Safety and efficacy of verinurad,a selective URAT1 inhibitor,for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan:Findings from two phase II trials[J].Modern rheumatology,2019,29(6):1042-1052.
[47] 杜格，蒋雨彤，古洁若.降尿酸药物研究进展[J].新医学，2017,48(6):369-374.
[48] 黄琳秋，江筠，楼觉人.尿酸氧化酶临床疗效和安全性评价[J].国际生物制品学杂志，2016,39(2):92-96.
[49] SALI G,KALAVAMPARA S V,KANDASAMY S G,et al.Genitourinary non-tuberculous mycobacterial (GU-NTM) infections:A single institution experience in South India[J].Indian Journal of Tuberculosis,2020,40(3):406-408.
[50] LIPSKY P E,CALABRESE L H,KAVANAUGHA,et al.Pegloticase immunogenicity:the relationship between efficacy and antibody development in patients treated for refractory chronic gout[J].Arthritis Res Ther,2014,16(2):104-108.
[51] 高红勤，朱良春，朱婉华，等.朱良春治疗痛风经验应用体会[J].中国中医药信息杂志，2014,21(8):114-115.
[52] 杜晓萌，余红蕾，钱先.钱先教授治疗痛风经验[J].林中医药，2018,38(3):279-281.
[53] 徐红，罗恒，陈坚翱.基于代谢组学对中药芪苓颗粒治疗高尿酸血症的疗效及安全性评价[J].中华中医药杂志，2017,32(10):4644-4647.
[54] 苗兵.针刺结合降尿酸方防治高尿酸血症的临床研究[J].黑龙江医学，2016,40(9):853-854.
[55] 李博.穴位埋线对腹型肥胖患者高尿酸血症的影响[D].广州：广州中医药大学，2010.
[56] 鲍玉晓.针刺放血联合冰片外敷治疗急性痛风性关节炎临床观察[J].湖北中医杂志，2015,37(2):17-18.
基本信息:
DOI：
中图分类号:R589.7
引用信息:
[1]孙泽锐,王宣军,盛军.高尿酸血症研究进展[J].云南民族大学学报(自然科学版),2021,30(02):135-142+156.
基金信息:
国家自然科学基金(31960075,21602196); 云南省科技厅基金(2017ZF003,2017FG001(-046),2017FD084)